Aldeyra Therapeutics (NASDAQ:ALDX) is scheduled to post its quarterly earnings results before the market opens on Thursday, August 8th. Analysts expect Aldeyra Therapeutics to post earnings of ($0.51) per share for the quarter.
Aldeyra Therapeutics (NASDAQ:ALDX) last announced its earnings results on Thursday, May 9th. The biotechnology company reported ($0.39) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.41) by $0.02. On average, analysts expect Aldeyra Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Shares of ALDX traded up $0.01 during mid-day trading on Tuesday, hitting $5.17. 19,070 shares of the company’s stock were exchanged, compared to its average volume of 162,194. Aldeyra Therapeutics has a 52 week low of $4.99 and a 52 week high of $16.70. The stock has a 50-day moving average of $5.89. The stock has a market capitalization of $149.55 million, a price-to-earnings ratio of -2.89 and a beta of 0.50.
Several research analysts have recently commented on ALDX shares. ValuEngine raised shares of Aldeyra Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, June 22nd. Canaccord Genuity reaffirmed a “buy” rating and set a $20.00 target price (down previously from $35.00) on shares of Aldeyra Therapeutics in a research note on Friday, May 10th. Zacks Investment Research raised shares of Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, July 23rd. Finally, Cantor Fitzgerald set a $33.00 target price on shares of Aldeyra Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, June 25th. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $31.00.
Aldeyra Therapeutics Company Profile
Aldeyra Therapeutics, Inc, a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency.
Featured Story: Conference Calls
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.